Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients

Blumer, Ian; Novak, Lucia M.; Edelman, Steven V.; Cavaiola, Tricia Santos

doi:10.2337/cd18-0102

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, we have seen the introduction of fixed-ratio combinations (FRCs) of long-acting insulin and short-acting GLP-1 RA preparations in which both medications are administered via a single delivery pen at a pre-determined ratio. With these formulations, the GLP-1 RA dosage is adjusted automatically as patients “dial in” their prescribed basal insulin dosages [ 89 ]. Currently, two different FRC products have received FDA and EMA approval: iDegLira (insulin degludec/liraglutide) and iGlarLixi (insulin glargine/lixisenatide).…”

Section: Glp-1 Ra In Combination With Insulin Therapymentioning

confidence: 99%

The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review

McGill,

Hirsch,

Parkin

et al. 2024

Diabetes Ther

View full text Add to dashboard Cite

Early initiation of intensive insulin therapy has been demonstrated to be effective in controlling glycemia and possibly preserving beta-cell function. Innovations in insulin formulations and delivery systems continue. However, we have seen an acceleration in the development of new classes of diabetes medications for individuals with type 2 diabetes and obesity, such as, for example, glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These formulations have been shown to confer significant benefits in achieving good glycemic control with reduced hypoglycemia risk, weight loss, and cardiorenal protection. Therefore, it is reasonable to question whether there is still a role for insulin therapy in the management of type 2 diabetes. However, there are clear limitations inherent to GLP-1 RA therapy, including high rates of suboptimal adherence and treatment discontinuation due to high cost and side effects, which diminish long-term efficacy, and supply issues. In addition, newer formulations have shown improvements in convenience and tolerability, and have been shown to be even more effective when used in conjunction with basal insulin. In this narrative review, we discuss current evidence that supports GLP-1 RA use in combination with insulin therapy and the potential pitfalls of reliance on GLP-1 RAs as a substitute for insulin therapy.

show abstract

Section: Glp-1 Ra In Combination With Insulin Therapymentioning

confidence: 99%